Publications by authors named "Belen Hernandez-Muniesa"
Article Synopsis
- The study aims to assess the health-related quality of life in patients with common immune-mediated inflammatory diseases like IBD, psoriasis, psoriatic arthritis, rheumatoid arthritis, and spondyloarthropathies in Spain, considering factors affecting their quality of life.
- The research involved 578 adult patients and utilized various questionnaires, including EQ-5D-5L, to evaluate their quality of life, revealing significant differences based on the type of disease.
- Results showed that psoriasis and IBD patients experienced a better quality of life compared to those with psoriatic arthritis, rheumatoid arthritis, and spondyloarthropathies, with worse outcomes linked to female gender, more severe disease, older age, and numerous prior treatments. *
Article Synopsis
- - The study aimed to assess the quality of life in patients with common immune-mediated inflammatory diseases in Spain (like IBD, psoriasis, RA, etc.) and identify factors affecting their quality of life.
- - Conducted in four hospitals in Madrid, this observational study analyzed 578 adult patients using various questionnaires to measure aspects like mobility, pain, and anxiety.
- - The results indicated that patients with psoriasis and inflammatory bowel disease had better quality of life scores compared to those with psoriatic arthritis and rheumatoid arthritis, and factors such as gender, disease severity, age, and treatment persistence significantly impacted quality of life.
Baricitinib and imatinib are considered therapies for coronavirus disease 2019 (COVID-19), but their ultimate clinical impact remains to be elucidated, so our objective is to determine whether these kinase inhibitors provide benefit when added to standard care in hospitalized COVID-19 patients. Phase-2, open-label, randomized trial with a pick-the-winner design conducted from September 2020 to June 2021 in a single Spanish center. Hospitalized adults with COVID-19 pneumonia and a symptom duration ≤10 days were assigned to 3 arms: imatinib (400 mg qd, 7 days) plus standard-care, baricitinib (4 mg qd, 7 days) plus standard-care, or standard-care alone.
View Article and Find Full Text PDFArticle Synopsis
- The study evaluates patient satisfaction with healthcare among individuals suffering from prevalent immune-mediated inflammatory diseases (IMIDs) in Spain, specifically focusing on conditions like inflammatory bowel disease (IBD), psoriasis (Ps), psoriatic arthritis (PsA), rheumatoid arthritis (RA), and spondyloarthropathies (SpAs).
- Conducted in four hospitals within the Community of Madrid, the research involved 578 adult patients using questionnaires to assess their experiences and health-related quality of life.
- Results indicated a general satisfaction score of 6.6 out of 10, with RA patients reporting the lowest satisfaction, while factors like productive interactions and patient self-management received higher scores in terms of healthcare experience.